About Spark Therapeutics (NASDAQ:ONCE)
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of CLN2 disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and other neurodegenerative diseases. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Trailing P/E Ratio-10.67
Forward P/E Ratio-24.44
Sales & Book Value
Annual Sales$12.07 million
Price / Sales250.98
Price / CashN/A
Book Value$13.88 per share
Price / Book5.86
EPS (Most Recent Fiscal Year)($7.63)
Return on Equity-59.38%
Return on Assets-51.66%
Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions
What is Spark Therapeutics' stock symbol?
Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."
How were Spark Therapeutics' earnings last quarter?
Spark Therapeutics (NASDAQ:ONCE) issued its quarterly earnings results on Tuesday, February, 20th. The biotechnology company reported ($1.73) EPS for the quarter, hitting the consensus estimate of ($1.73). The biotechnology company earned $7.41 million during the quarter, compared to analyst estimates of $9.53 million. Spark Therapeutics had a negative net margin of 2,100.80% and a negative return on equity of 59.38%. View Spark Therapeutics' Earnings History.
What price target have analysts set for ONCE?
20 equities research analysts have issued twelve-month price objectives for Spark Therapeutics' stock. Their predictions range from $40.00 to $113.00. On average, they expect Spark Therapeutics' share price to reach $70.5789 in the next twelve months. View Analyst Ratings for Spark Therapeutics.
What are Wall Street analysts saying about Spark Therapeutics stock?
Here are some recent quotes from research analysts about Spark Therapeutics stock:
- 1. Mizuho analysts commented, "We expect the first Luxturna patients to be treated in 2Q18 in the U.S. while regulatory action is expected by the EMA in 3Q18." (2/21/2018)
- 2. Cantor Fitzgerald analysts commented, "We believe Spark’s licensing and supply agreement with Novartis (NVS – Not Covered) for LUXTURNA’s ex-U.S. rights further emphasizes the significant value of the approved gene therapy’s commercial opportunity." (1/24/2018)
- 3. Chardan Capital analysts commented, "We also see it as a important positive on Spark corporate governance that, e.g. during the panel, Spark provided caution to the panel attendees when panelists seemed interested in the potential for Luxturna re-treatment to further improve vision by treating more of the retina. (Spark noted that the company had not yet generated such data and responsibly urged caution.) After the unanimous backing of the panel, Luxturna, which has a PDUFA date of 12 January 2018, could achieve a number of firsts if approved, i.e." (10/13/2017)
- 4. Cowen Inc analysts commented, "The FDA’s briefing documents appear mostly benign with most discussion centered." (10/10/2017)
Who are some of Spark Therapeutics' key competitors?
Some companies that are related to Spark Therapeutics include Bio-Techne (TECH), China Biologic Products (CBPO), arGEN-X BV (ARGX), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Repligen (RGEN), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT), Atara Biotherapeutics (ATRA), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD), DBV Technologies (DBVT), Iovance Biotherapeutics (IOVA), REGENXBIO (RGNX) and Cellectis (CLLS).
Who are Spark Therapeutics' key executives?
Spark Therapeutics' management team includes the folowing people:
- Mr. Jeffrey D. Marrazzo M.B.A., M.P.A., Co-Founder, CEO & Director (Age 39)
- Dr. Katherine A. High, Co-Founder, Pres and Chief Scientific Officer (Age 66)
- Mr. Stephen W. Webster, Chief Financial Officer (Age 57)
- Mr. John Furey, Chief Operating Officer (Age 53)
- Mr. Daniel R. Faga, Chief Bus. Officer (Age 38)
When did Spark Therapeutics IPO?
(ONCE) raised $88 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.
Has Spark Therapeutics been receiving favorable news coverage?
News articles about ONCE stock have trended somewhat positive recently, according to Accern. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Spark Therapeutics earned a news impact score of 0.11 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 44.75 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Spark Therapeutics?
Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spark Therapeutics' stock price today?
One share of ONCE stock can currently be purchased for approximately $81.39.
How big of a company is Spark Therapeutics?
Spark Therapeutics has a market capitalization of $3.03 billion and generates $12.07 million in revenue each year. The biotechnology company earns $-253,480,000.00 in net income (profit) each year or ($7.63) on an earnings per share basis. Spark Therapeutics employs 315 workers across the globe.
How can I contact Spark Therapeutics?
Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected]
MarketBeat Community Rating for Spark Therapeutics (ONCE)MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe ONCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Spark Therapeutics (NASDAQ:ONCE) Price Target and Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
20 Wall Street analysts have issued ratings and price targets for Spark Therapeutics in the last 12 months. Their average twelve-month price target is $70.5789, suggesting that the stock has a possible downside of 13.28%. The high price target for ONCE is $113.00 and the low price target for ONCE is $40.00. There are currently 5 hold ratings and 15 buy ratings for the stock, resulting in a consensus rating of "Buy."
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.75||2.75||2.68||2.83|
|Ratings Breakdown: ||0 Sell Rating(s)|
5 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
4 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
1 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$70.5789||$70.5789||$74.6667||$91.6471|
|Price Target Upside: ||13.28% downside||9.42% upside||44.90% upside||8.81% upside|
Spark Therapeutics (NASDAQ:ONCE) Consensus Price Target History
Spark Therapeutics (NASDAQ:ONCE) Analyst Ratings History
(Data available from 4/21/2016 forward)
Spark Therapeutics (NASDAQ:ONCE) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Spark Therapeutics (NASDAQ ONCE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.30%
Spark Therapeutics (NASDAQ ONCE) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|4/18/2018||John Furey||COO||Sell||13,277||$82.52||$1,095,618.04||2,277|| |
|4/12/2018||John Furey||COO||Sell||20,000||$77.51||$1,550,200.00||20,000|| |
|12/11/2017||John Furey||COO||Sell||18||$46.33||$833.94|| |
|12/8/2017||John Furey||COO||Buy||18||$73.48||$1,322.64|| |
|11/28/2017||Katherine A High||Insider||Sell||5,000||$71.32||$356,600.00||215,000|| |
|11/16/2017||Stephen W Webster||CFO||Sell||10,000||$70.14||$701,400.00||12,500|| |
|11/13/2017||Barge Joseph La||Insider||Sell||5,500||$71.44||$392,920.00||8,146|| |
|11/13/2017||Jeffrey D Marrazzo||CEO||Sell||20,000||$71.54||$1,430,800.00||250,000|| |
|11/9/2017||Barge Joseph La||Insider||Sell||3,309||$71.31||$235,964.79||8,146|| |
|10/31/2017||Katherine A High||Insider||Sell||5,000||$83.30||$416,500.00||215,000|| |
|10/24/2017||Daniel Faga||Insider||Sell||7,500||$80.96||$607,200.00||6,000|| |
|10/20/2017||Daniel Faga||Insider||Sell||6,000||$79.95||$479,700.00||6,000|| |
|9/26/2017||Katherine A High||Insider||Sell||5,000||$86.16||$430,800.00||215,000|| |
|9/21/2017||Hospital Of Philade Children's||Director||Sell||1,000,000||$84.63||$84,630,000.00||3,928,707|| |
|9/19/2017||Daniel Faga||Insider||Sell||1,500||$85.00||$127,500.00||1,500|| |
|9/12/2017||Daniel Faga||Insider||Sell||6,000||$82.50||$495,000.00||6,000|| |
|9/7/2017||Daniel Faga||Insider||Sell||3,000||$85.02||$255,060.00||3,000|| |
|9/5/2017||Barge Joseph La||Insider||Sell||5,500||$81.00||$445,500.00||10,825|| |
|8/29/2017||Katherine A High||Insider||Sell||10,000||$80.25||$802,500.00||220,000|| |
|8/23/2017||Jeffrey D Marrazzo||CEO||Sell||21,350||$80.01||$1,708,213.50||251,350|| |
|8/15/2017||Stephen W Webster||CFO||Sell||10,000||$79.38||$793,800.00||12,500|| |
|8/11/2017||Jeffrey D Marrazzo||CEO||Sell||15,000||$75.10||$1,126,500.00||245,000|| |
|8/2/2017||Jeffrey D Marrazzo||CEO||Sell||28,650||$80.01||$2,292,286.50||258,650|| |
|7/31/2017||Stephen W Webster||CFO||Sell||2,337||$71.12||$166,207.44||4,837|| |
|7/25/2017||Katherine A High||Insider||Sell||10,000||$72.53||$725,300.00||220,000|| |
|7/24/2017||Anand Mehra||Director||Sell||211,858||$70.15||$14,861,838.70|| |
|7/24/2017||Daniel Faga||Insider||Sell||3,000||$70.00||$210,000.00||3,000|| |
|7/5/2017||Jeffrey D Marrazzo||CEO||Sell||5,669||$65.00||$368,485.00||235,669|| |
|6/29/2017||Daniel Faga||Insider||Sell||4,500||$62.71||$282,195.00||4,500|| |
|6/27/2017||Katherine A High||Insider||Sell||10,000||$60.96||$609,600.00||220,000|| |
|6/21/2017||Anand Mehra||Director||Sell||6,302||$65.00||$409,630.00|| |
|6/21/2017||Jeffrey D Marrazzo||CEO||Sell||9,331||$65.00||$606,515.00||230,534|| |
|6/19/2017||Katherine A High||Insider||Sell||10,000||$60.00||$600,000.00||220,000|| |
|6/19/2017||Stephen W Webster||CFO||Sell||7,663||$60.00||$459,780.00||10,163|| |
|6/7/2017||Barge Joseph La||General Counsel||Sell||5,000||$55.00||$275,000.00||9,567|| |
|4/25/2017||Katherine A High||Insider||Sell||15,000||$55.33||$829,950.00||212,060|| |
|4/25/2017||Stephen W Webster||CFO||Sell||10,000||$55.18||$551,800.00||4,398|| |
|4/24/2017||Katherine A High||Insider||Sell||2,060||$55.01||$113,320.60||212,060|| |
|4/24/2017||Stephen W Webster||CFO||Sell||1,898||$55.00||$104,390.00||4,398|| |
|4/3/2017||Barge Joseph La||General Counsel||Sell||5,000||$52.73||$263,650.00||10,325|| |
|3/1/2017||Anand Mehra||Director||Sell||84,654||$65.02||$5,504,203.08|| |
|3/1/2017||Barge Joseph La||General Counsel||Sell||5,000||$64.41||$322,050.00||10,325|| |
|2/28/2017||Anand Mehra||Director||Sell||25,274||$65.02||$1,643,315.48|| |
|2/27/2017||Anand Mehra||Director||Sell||41,910||$65.02||$2,724,988.20|| |
|2/16/2017||Anand Mehra||Director||Sell||35,347||$65.03||$2,298,615.41|| |
|2/7/2017||Anand Mehra||Director||Sell||25,334||$65.06||$1,648,230.04|| |
|12/16/2016||Anand Mehra||Director||Sell||349,656||$53.46||$18,692,609.76|| |
|12/15/2016||Barge Joseph La||Insider||Sell||3,000||$52.98||$158,940.00||8,325|| |
|12/13/2016||Anand Mehra||Director||Sell||122,532||$55.17||$6,760,090.44|| |
|11/14/2016||Katherine A High||Insider||Sell||10,000||$60.30||$603,000.00||210,000|| |
|10/17/2016||Jeffrey D Marrazzo||CEO||Sell||5,000||$54.66||$273,300.00||235,000|| |
|10/3/2016||Barge Joseph La||Insider||Sell||3,000||$60.14||$180,420.00||8,325|| |
|9/16/2016||Jeffrey D Marrazzo||CEO||Sell||10,000||$62.68||$626,800.00||240,000|| |
|9/15/2016||Katherine A High||Insider||Sell||10,000||$60.37||$603,700.00||220,500|| |
|8/16/2016||Hospital Of Philade Children's||Director||Sell||1,000,000||$60.90||$60,900,000.00||5,768,707|| |
|8/11/2016||Anand Mehra||Director||Sell||29,963||$60.13||$1,801,675.19|| |
|8/11/2016||Jeffrey D Marrazzo||CEO||Sell||16,970||$60.04||$1,018,878.80||236,971|| |
|8/10/2016||Katherine A High||Insider||Sell||1,890||$60.00||$113,400.00||240,000|| |
|8/8/2016||Anand Mehra||Director||Sell||100||$60.47||$6,047.00|| |
|8/8/2016||Jeffrey D Marrazzo||CEO||Sell||900||$60.24||$54,216.00||230,100|| |
|8/8/2016||Katherine A High||Insider||Sell||500||$60.24||$30,120.00||242,290|| |
|8/4/2016||Anand Mehra||Director||Sell||5,064||$60.00||$303,840.00|| |
|8/3/2016||Jeffrey D Marrazzo||CEO||Sell||16,530||$60.02||$992,130.60||242,348|| |
|8/3/2016||Katherine A High||Insider||Sell||17,610||$60.02||$1,056,952.20||246,017|| |
|8/1/2016||Anand Mehra||Director||Sell||22,665||$60.03||$1,360,579.95|| |
|8/1/2016||Jeffrey D Marrazzo||CEO||Sell||12,348||$60.03||$741,250.44||242,348|| |
|8/1/2016||Katherine A High||Insider||Sell||13,983||$60.02||$839,259.66||246,017|| |
|7/18/2016||Jeffrey D Marrazzo||CEO||Sell||5,000||$52.53||$262,650.00||235,000|| |
|7/15/2016||Coelho Rogerio Vivaldi||Insider||Sell||7,000||$53.03||$371,210.00||19,716|| |
|7/5/2016||Barge Joseph La||Insider||Sell||3,000||$52.24||$156,720.00||8,325|| |
|6/20/2016||Hospital Of Philade Children's||Major Shareholder||Sell||1,000,000||$42.30||$42,300,000.00||6,768,707|| |
|6/15/2016||Jeffrey D Marrazzo||CEO||Sell||5,000||$46.49||$232,450.00||235,000|| |
|5/31/2016||Anand Mehra||Director||Sell||500||$60.00||$30,000.00|| |
|5/23/2016||Katherine A High||Insider||Sell||10,000||$54.42||$544,200.00||270,100|| |
|5/20/2016||Barge Joseph La||Insider||Sell||10,000||$47.65||$476,500.00||12,825|| |
|5/20/2016||Stephen W Webster||CFO||Sell||20,000||$50.39||$1,007,800.00||22,500|| |
|5/19/2016||Jeffrey D Marrazzo||CEO||Sell||25,000||$46.01||$1,150,250.00||255,000|| |
|4/21/2016||Coelho Rogerio Vivaldi||Insider||Sell||7,000||$40.02||$280,140.00||19,716|| |
|12/28/2015||Hospital Of Philade Children's||Major Shareholder||Sell||131,505||$44.18||$5,809,890.90||7,768,707|| |
|12/21/2015||Hospital Of Philade Children's||Major Shareholder||Sell||1,000,000||$44.18||$44,180,000.00||7,900,212|| |
|12/1/2015||Katherine A High||Insider||Sell||10,000||$55.31||$553,100.00||280,000|| |
|11/27/2015||Anand Mehra||Director||Sell||22,961||$60.01||$1,377,889.61|| |
|11/16/2015||Katherine A High||Insider||Sell||10,000||$53.77||$537,700.00||290,000|| |
|11/12/2015||Anand Mehra||Director||Sell||130,605||$60.11||$7,850,666.55|| |
|10/14/2015||Katherine A. High||insider||Sell||30,000||$49.34||$1,480,200.00||300,000|| |
|10/13/2015||Katherine A. High||insider||Sell||10,000||$48.00||$480,000.00||300,000|| |
|10/12/2015||Jeffrey D. Marrazzo||CEO||Sell||75,000||$48.35||$3,626,250.00||230,000|| |
|10/9/2015||Jeffrey D. Marrazzo||CEO||Sell||75,000||$47.82||$3,586,500.00||305,000|| |
|10/8/2015||Anand Mehra||Director||Sell||529,544||$45.46||$24,073,070.24|| |
|10/7/2015||Coelho Rogerio Vivaldi||insider||Sell||41,000||$48.85||$2,002,850.00||5,383|| |
|10/7/2015||Stephen W. Webster||CFO||Sell||20,000||$48.86||$977,200.00||2,500|| |
|10/7/2015||Steven Altschuler||Director||Buy||5,000||$49.11||$245,550.00||5,000|| |
|2/4/2015||Anand Mehra||Director||Buy||225,000||$23.00||$5,175,000.00|| |
|2/4/2015||Hospital Of Philade Children's||Major Shareholder||Buy||100,000||$23.00||$2,300,000.00|| |
|2/4/2015||Stephen W Webster||CFO||Buy||2,500||$23.00||$57,500.00|| |
Spark Therapeutics (NASDAQ ONCE) News Headlines
Spark Therapeutics (NASDAQ:ONCE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Spark Therapeutics (NASDAQ:ONCE) Income Statement, Balance Sheet and Cash Flow Statement
Spark Therapeutics (NASDAQ ONCE) Stock Chart for Saturday, April, 21, 2018